Seeking Alpha
23 Nov 2025, 10:36 UTC · 51w ago
Pharvaris: Biotech With De-Risked Phase 3 Readout Coming, Initiating With A Buy Rating
Impact · against what's priced in
Pharvaris is positioned for a potential valuation re-rating driven by a high-probability Phase 3 readout for Deucrictibant by year-end 2025. The catalyst is the transition from Phase 2 validation to pivotal data in a differentiated oral HAE franchise.
- PHVS+0.60
No priced-in read yet
- In context
The upcoming year-end 2025 Phase 3 data for Deucrictibant serves as a primary catalyst, with a projected 90%+ probability of success based on previous phase 2 results.
Read from the article alone





